
Interspinous process fixation versus posterior lumbar interbody fusion following decompression for single-level grade I degenerative spondylolisthesis: a retrospective propensity score-matched study

Received: 28 October 2025

Accepted: 9 January 2026

Published online: 30 January 2026

Cite this article as: Ma J., Li T., Shen N. *et al.* Interspinous process fixation versus posterior lumbar interbody fusion following decompression for single-level grade I degenerative spondylolisthesis: a retrospective propensity score-matched study. *J Orthop Surg Res* (2026). <https://doi.org/10.1186/s13018-026-06683-w>

Jingbo Ma, Tusheng Li, Nan Shen, Rigbat Rozi & Yu Ding

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

1 **Interspinous Process Fixation versus Posterior Lumbar**
2 **Interbody Fusion Following Decompression for Single-Level**
3 **Grade I Degenerative Spondylolisthesis: A Retrospective**
4 **Propensity Score-Matched Study**

5 Jingbo Ma ^{1, 2†}, Tusheng Li ^{1, 3†}, Nan Shen¹, Rigbat Rozi ¹, Yu Ding ^{1, 2, *}

6 ¹ Orthopedics of TCM Senior Department, The Sixth Medical Center of People's
7 Liberation Army General Hospital, Beijing, China

8 ² Navy Clinical College, Fifth School of Clinical Medicine, Anhui Medical University,
9 Hefei, China

10 ³ Department of Orthopedics, Beijing Chaoyang Hospital, Capital Medical
11 University, Beijing, China

12

13

14

15

16

17 [†]Jingbo Ma and Tusheng Li contributed equally to this work

18 **Corresponding author:** Yu Ding

19 Orthopedics of TCM Senior Department, The Sixth Medical Center of People's

20 Liberation Army General Hospital, Beijing 100048, China

21 **E-mail:** dingyu@301hospital.com.cn

22 **Abstract**

23 **Objective:** To compare clinical outcomes and radiographic parameters between
24 interspinous process fixation (ISPF) and posterior lumbar interbody fusion (PLIF)
25 in patients with single-level degenerative lumbar spinal stenosis (LSS) associated
26 with Meyerding Grade I spondylolisthesis.

27 **Methods:** We retrospectively analyzed 107 patients who underwent ISPF (n = 55)
28 or PLIF (n = 52) between January 2019 and January 2023. Propensity score
29 matching (PSM) was performed using covariates including age, sex, BMI,
30 symptom duration, smoking history, diabetes mellitus, hypertension, and
31 affected spinal level, resulting in 36 matched pairs. Clinical efficacy was evaluated
32 using the Visual Analog Scale (VAS), Oswestry Disability Index (ODI), Japanese
33 Orthopaedic Association (JOA) score, and Macnab criteria. Radiographic
34 assessments included lumbar lordosis (LL), pelvic incidence (PI), pelvic tilt (PT),
35 segmental angle (SA), and disc height (DH). All patients completed more than 24
36 months of follow-up.

37 **Results:** Post-matching analysis demonstrated good baseline balance (SMD <
38 0.20, P > 0.05). ISPF showed superior short-term outcomes, with significantly
39 greater improvement in VAS scores both immediately postoperatively (2.52 ± 1.39

40 vs. 3.21 ± 1.23 , $P=0.0078$) and at the 3-month follow-up (1.83 ± 1.31 vs. $2.54 \pm$
41 1.20, $P=0.0042$). Similarly, ODI favored ISPF at the immediate postoperative
42 evaluation (38.64 ± 8.86 vs. 42.17 ± 6.77 , $P=0.0221$) and at 3 months ($25.61 \pm$
43 8.84 vs. 30.15 ± 6.75 , $P=0.0035$), whereas no significant between-group
44 differences were observed at 1 year and at the final follow-up (both $P > 0.05$).
45 Radiographically, ISPF achieved superior LL ($45.13^\circ \pm 4.97$ vs. $40.37^\circ \pm 7.37$,
46 $P=0.0002$) and lower PT ($12.49^\circ \pm 7.62$ vs. $15.80^\circ \pm 8.26$, $P=0.0334$), whereas
47 PLIF demonstrated greater correction of the slip angle (SA: $10.99^\circ \pm 2.53$ vs.
48 $12.52^\circ \pm 1.48$, $P=0.0004$). Long-term clinical outcomes and patient satisfaction
49 rates were comparable (Macnab excellent-to-good: 86.11% ISPF vs. 83.33% PLIF,
50 $P=0.9420$).

51 **Conclusions:** ISPF provided better short-term clinical recovery and maintenance
52 of sagittal alignment, whereas PLIF offered greater slip correction. Both
53 procedures yielded comparable long-term clinical outcomes, supporting
54 individualized surgical decision-making in patients with degenerative LSS and
55 Grade I spondylolisthesis.

56 **Keywords:** Lumbar spinal stenosis; Degenerative lumbar spondylolisthesis;
57 Interspinous process fixation; Posterior lumbar interbody fusion; Propensity score
58 matching

59

60 **Introduction**

61 Degenerative lumbar spondylolisthesis (DLS) has emerged as a prevalent spinal
62 degenerative disorder whose incidence increases markedly with global population
63 aging[1]. Epidemiological studies have revealed that in the 66-70-year age group,
64 DLS affects approximately 15% of men and over 50% of women[2]. This condition
65 is characterized by anterior slippage of a superior vertebral body relative to the
66 adjacent inferior segment, often leading to spinal instability and neural
67 compression. Clinically, patients most commonly present with chronic low back
68 pain and radicular leg symptoms[3]. DLS often coexists with lumbar spinal
69 stenosis (LSS), exacerbating symptom severity and substantially impairing quality
70 of life[3,4]. Consequently, DLS places a significant burden on both patients and
71 healthcare systems worldwide.

72 Currently, surgical decompression combined with internal fixation or fusion
73 remains the mainstay treatment for DLS and LSS, aiming to alleviate symptoms
74 and improve functional outcomes. However, with global population aging, the
75 incidence of postoperative complications following spinal fusion procedures may
76 increase, which warrants increased clinical attention[5]. Conventional posterior
77 lumbar interbody fusion (PLIF) employs a pedicle screw-rod construct to achieve
78 segmental arthrodesis and restore spinal biomechanical stability. PLIF is widely
79 adopted in clinical practice and is associated with well-documented outcome
80 profiles[6]. However, long-term complications, particularly adjacent segment
81 degeneration (ASD) have raised increasing concerns[7]. With advances in
82 minimally invasive spine surgery, interspinous dynamic stabilization systems, such

83 as interspinous process fixation (ISPF) have gained clinical traction[8]. These
84 semi-rigid implants provide segmental support by bridging the spinous processes
85 while preserving partial physiological motion. Theoretically, dynamic stabilization
86 may mitigate ASD risk and has therefore attracted increasing interest[9].

87 Whereas PLIF offers robust segmental stability through interbody fusion, ISPF
88 aims to achieve symptom relief with less soft-tissue disruption. Both PLIF and ISPF
89 represent established surgical options for Meyerding Grade I lumbar
90 spondylolisthesis with concomitant LSS. Comparative mid- to long-term outcomes
91 between the two remain poorly characterized. ISPF may offer potential
92 advantages over PLIF, including reduced intraoperative blood loss, shorter
93 hospitalization, and lower perioperative complication rates[10]. However, direct
94 comparative studies assessing the clinical efficacy and safety of these techniques
95 are scarce. The current literature largely consists of small-scale prospective trials
96 or short-term follow-up studies, yielding a low level of evidence. Consequently,
97 mid- to long-term differences in clinical outcomes between PLIF and ISPF remain
98 inadequately characterized[11].

99 This retrospective comparative study systematically evaluated the mid-to-long-
100 term clinical outcomes and safety profiles of conventional PLIF versus ISPF in
101 patients with single-level degenerative LSS and Meyerding Grade I
102 spondylolisthesis over a 2-year follow-up. The objective of this study is to generate
103 robust evidence to refine surgical strategy selection and optimize treatment
104 strategies for DLS.

105 **Materials and methods**

106 **Study design and patients**

107 We retrospectively reviewed the medical records of patients with single-level
108 degenerative LSS and Meyerding Grade I spondylolisthesis who underwent either
109 ISPF or PLIF at our institution between January 2019 and January 2023. This study
110 was approved by the Ethics Review Committee of the Sixth Medical Center of the
111 General Hospital of the Chinese People's Liberation Army (Approval No. HZKY-PJ-
112 2025-29).

113 The inclusion criteria were as follows: (1) presence of low back pain and/or
114 radicular leg pain, with or without neurogenic claudication; (2) radiographic
115 evidence (X-ray or CT) of single-level Grade I spondylolisthesis with concurrent
116 LSS at the same level, confirmed by MRI or CT showing absolute stenosis (cross-
117 sectional area [CSA] $< 75 \text{ mm}^2$) or relative stenosis (CSA $< 100 \text{ mm}^2$); (3) failure
118 of conservative treatment ≥ 3 months; (4) age > 18 years; (5) a follow-up duration
119 of ≥ 24 months with complete clinical records. The exclusion criteria were as
120 follows: (1) presence of spinal tuberculosis, tumor, infection, or trauma; (2)
121 diagnosed osteoporosis with a T-score < -2.5 ; (3) history of previous lumbar spine
122 surgery; (4) presence of spinal scoliosis with a Cobb angle $> 25^\circ$; (5) multi-level
123 pathology involving more than two spinal segments; (6) inability to tolerate
124 surgical intervention.

125 Based on the inclusion criteria, 107 patients were included in the study cohort: 55

126 in the ISPF group and 52 in the PLIF group. All procedures were performed by a
127 single senior spine surgeon to minimize variability in surgical technique.
128 Propensity score matching (PSM) was performed to minimize baseline imbalances
129 between groups[12]. Propensity scores were estimated via a logistic regression
130 model including the following baseline covariates: age, sex, body mass index (BMI),
131 symptom duration, hypertension, diabetes mellitus, smoking history, and affected
132 spinal level (L3-L4, L4-L5, or L5-S1). Follow-up duration was descriptively
133 compared descriptively between groups after matching to confirm comparable
134 follow-up periods but was not included in the matching model to avoid post-
135 treatment bias. A 1:1 nearest-neighbor matching algorithm with a caliper width of
136 0.02 and no replacement was applied. Group balance was evaluated using
137 standardized mean differences (SMDs), with an SMD < 0.2 indicating adequate
138 balance[13] (Table 1).

139 **Surgical procedures**

140 **PLIF approach**

141 Posterior lumbar interbody fusion (PLIF) was performed through a midline
142 posterior incision of approximately 3-6 cm, with subperiosteal elevation of the
143 erector spinae muscles from the laminae bilaterally to expose the spinous
144 processes, laminae, facet joints, and when necessary, the transverse processes at
145 one or two adjacent levels (e.g., for an L4-L5 PLIF: the L4 spinous process and
146 lamina, the L3-L4 and L4-L5 facets joints, and the L4-L5 transverse processes).
147 The spinous process at the index level was removed, followed by a laminectomy to

148 decompress the thecal sac in the midline and to visualize the exiting nerve roots
149 on both sides; the facet joints were undercut (medial facetectomy) as required to
150 enlarge the lateral recess and neural foramina. The nerve roots were then gently
151 retracted medially to access the posterior annulus fibrosus, bilateral annulotomies
152 were performed, the disc material was removed, and the endplates were prepared
153 to create an optimal fusion bed while preserving the subchondral bone integrity;
154 the same steps were repeated contralaterally to facilitate bilateral interbody work.

155 Two interbody spacers (one per side), each packed with a bone graft, were
156 inserted into the disc space to restore disc height and neural foraminal dimensions,
157 and final segmental stabilization was achieved with bilateral pedicle screws placed
158 in the vertebrae above and below the fused level and connected by rods to support
159 fusion across the vertebral bodies. The implant position and alignment were
160 confirmed under fluoroscopy, hemostasis was secured, and layered closure was
161 performed [14].

162 **ISPF approach**

163 An interspinous process fusion plate (BacFuse Spinous Process Fusion Plate;
164 SpireTM Stabilization System) was used for distraction and posterior column fusion.
165 The implant consists of a central hollow body spanning the midportions of adjacent
166 spinous processes and bilateral flanges with multiple spikes; once seated, the
167 spikes are secured into the cranial and caudal spinous processes, and the lumen
168 is packed with a bone graft to promote fusion. The available sizes range from 8 to
169 16 mm to achieve the desired distraction. The instrument set includes a

170 compressor, inserter, driver, protective sleeve, rasp, and sequential dilators.

171 Patients underwent spinal or combined spinal-epidural anesthesia and were

172 positioned prone. Through a midline posterior approach, the spinous processes

173 were exposed; the interspinous ligament was divided while the supraspinous

174 ligament was preserved. The interspinous interval was sequentially dilated and

175 measured intraoperatively to select the appropriate implant size. When indicated

176 for stenosis, fenestration with partial laminectomy provided neural decompression.

177 Cem-Ostetic® bone graft (Berkeley Advanced Biomaterials, Berkeley, CA), a two-

178 component system comprising liquid and solid components (hydroxyapatite, β -

179 tricalcium phosphate, and calcium sulfate), was prepared and packed into the

180 device lumen. The plate was introduced from one side over a sleeve, and

181 compressed into final position, and the titanium spikes were locked to the adjacent

182 spinous processes. Fluoroscopic imaging verified the position, distraction, and

183 fixation prior to closure [15].

184 **Data collection and measurements**

185 Demographic and perioperative data for matched patients were collected. The

186 perioperative data included the operative time, fluoroscopy time, intraoperative

187 blood loss, length of hospital stay, and total length of incision. All patients were

188 followed up regularly for more than two years, including clinical functional scores,

189 imaging data, and complications. Complications were systematically recorded and

190 classified as early (<90 days after the index surgery) or late (≥ 90 days). Early

191 events included postoperative low back pain and lower-limb pain requiring


192 additional intervention, surgical-site infection, dural tear, disc-space infection, and
193 new/worsened neurologic deficit; late events included implant failure and
194 reoperation.

195 **Clinical evaluation**

196 Pain and functional outcomes were assessed using the Visual Analog Scale (VAS),
197 Oswestry Disability Index (ODI), and Japanese Orthopaedic Association (JOA)
198 score at five time points: preoperatively, immediately postoperatively, and at 3
199 months, 1 year, and final follow-up. Overall recovery and patient satisfaction at
200 the last follow-up were further evaluated according to the modified Macnab
201 criteria [16-19].

202 **Imaging measurements**

203 All patients underwent standardized X-ray, CT, and MRI preoperatively,
204 immediately postoperatively, at 3 months, at 1 year, and at the final follow-up. The
205 following parameters were obtained on lateral radiographs or reconstructed CT
206 images: lumbar lordosis (LL), pelvic incidence (PI), pelvic tilt (PT), segmental
207 angle (SA), disc height (DH) [20-25]. All radiographic measurements were
208 performed independently by two blinded observers, and the average of the two
209 readings was used for analysis. Figure 1 illustrates a schematic diagram of the
210 imaging measurements.



211 **Figure 1.** Schematic illustration of SA, DH, and LL measurements. (A)
 212 Measurement of segmental angle (SA): a, upper endplate line of the slipped
 213 vertebra; b, lower endplate line of the inferior vertebra; c, angle formed between
 214 lines a and b, defined as SA. (B) Measurement of lumbar lordosis (LL) and disc
 215 height (DH): d, upper endplate of L1; e, sacral endplate of S1; the angle between
 216 d and e is defined as LL. f, anterior disc height; g, posterior disc height; the
 217 average of f and g is defined as DH.

218

219 **Statistical analysis**

220 Statistical analyses were conducted using SPSS version 27.0 (IBM Corp., Armonk,
 221 NY, USA). Continuous variables were reported as means \pm standard deviations
 222 (SDs) and compared using independent-sample t tests. Categorical variables were
 223 compared using χ^2 tests. In addition, PSM was performed in R (MatchIt and cobalt
 224 packages; R Foundation for Statistical Computing, Vienna, Austria). A two-tailed

225 P value < 0.05 was considered statistically significant.

226

227

228 **Results**

229 **Baseline characteristics before and after propensity score matching**

230 The baseline demographic characteristics of the two groups before matching are
 231 shown in Table 1. Before matching, 107 patients with single-level LSS were
 232 enrolled, including 55 in the ISPF group and 52 in the PLIF group. SMD ≤ 0.20
 233 and $P > 0.05$ were considered to indicate adequate covariate balance. Two

Variable	PLIF Group	ISPF Group	P-value	SMD
Age	61.13 ± 6.71	58.43 ± 6.49	0.0366*	0.4092*
BMI	25.09 ± 2.62	24.04 ± 2.36	0.0313*	0.4216*
Disease Duration	28.16 ± 5.54	30.30 ± 5.25	0.0425*	0.3969*
Follow-Up Time	45.14 ± 2.05	45.90 ± 2.31	0.0762	0.3470*
Sex	22 (42.31%)	26 (47.27%)	0.7477	0.0998
Hypertension	27 (51.92%)	28 (50.91%)	1.0000	0.0203
Diabetes	17 (32.69%)	24 (43.64%)	0.3346	0.2253*
Smoking	42 (80.77%)	38 (69.09%)	0.2431	0.2694*
L3-L4	9 (17.31%)	10 (18.18%)	1.0000	0.0229
L4-L5	37 (71.15%)	37 (67.27%)	0.8219	0.0841
L5-S1	6 (11.54%)	8 (14.55%)	0.8617	0.0893
□	□	□	□	□

234 variables remained imbalanced prior to matching: symptom duration (SMD =
 235 0.370, $P = 0.048$) and age (SMD = 0.206, $P = 0.291$). BMI, smoking history, and
 236 diabetes mellitus demonstrated SMDs near the threshold (0.15–0.19).
 237 Consequently, these variables were incorporated into the propensity score model
 238 to improve baseline comparability.


239 **Table 1** Baseline characteristics before PSM

240 Using 1:1 nearest-neighbor propensity score matching with a caliper width of 0.02
 241 and no replacement, 36 matched pairs ($n = 72$) were obtained. After matching,
 242 nearly all covariates had SMDs ≤ 0.20 and $P > 0.05$, except for diabetes (SMD =
 243 0.211), indicating adequate balance between the ISPF and PLIF groups for age,
 244 BMI, symptom duration, smoking history, and affected spinal level distribution
 245 (Table 2). Mean follow-up duration was also comparable between groups ($P >$
 246 0.05), confirming similar observation periods. The Love plot (Figure 2)
 247 demonstrated a marked leftward shift in the SMD distributions after matching,
 248 further confirming the effectiveness of the matching procedure.

249 **Table 2** Baseline characteristics after PSM

Variable	PLIF Group	ISPF Group	P-value	SMD
Age	59.23 ± 6.91	59.60 ± 6.06	0.8261	0.0579
BMI	24.43 ± 2.16	24.18 ± 2.27	0.6695	0.1127
Disease Duration	30.74 ± 4.69	30.29 ± 5.68	0.7461	0.0854
Follow-Up Time	45.44 ± 2.06	45.57 ± 2.08	0.8122	0.0627
Sex	15 (41.67%)	15 (41.67%)	1.0000	0.0000
Hypertension	17 (47.22%)	19 (52.78%)	0.6374	0.1113
Diabetes	16 (44.44%)	12 (33.33%)	0.3336	0.2294
Smoking	26 (72.22%)	25 (69.44%)	0.7954	0.0611
L3-L4	8 (22.22%)	6 (16.67%)	0.5515	0.1407
L4-L5	25 (69.44%)	25 (69.44%)	1.0000	0.0000
L5-S1	3 (10.34%)	5 (13.89%)	0.4533	0.1775
□	□	□	□	□

250



251 **Figure 2.** Covariate balance before (red) and after (blue) propensity score
 252 matching, as assessed by the standardized mean difference (SMD).

253

254


255 **Image measurements**

256 The comparison of the imaging data between the groups is shown in Table 3 and
 257 Figure 3. Preoperatively, the ISPF and PLIF groups did not differ significantly in
 258 LL, PT, SA, or DH (all $P > 0.05$).

259 **Table 3** Comparison of radiographic parameters of DLS-LSS patients between 2

260 groups

261

262 **Figure 3.** Comparison of radiographic parameters between the ISPF and PLIF

263 groups at different time points. Lumbar lordosis (LL), pelvic incidence (PI), pelvic
264 tilt (PT), segmental angle (SA), and disc height (DH) were measured
265 preoperatively, postoperatively, at 3 months, 12 months, and at the last follow-up.

266 * $P < 0.05$ indicates statistical significance at the corresponding time point.

267

268 However, the PI was greater in the PLIF group than in the ISPF group ($P = 0.0159$).

269 At 3 months postoperatively, both cohorts exhibited significant improvements
270 compared with baseline in LL, PT, SA, and DH (all $P < 0.05$), with no intergroup
271 differences observed at this time point (all $P > 0.05$).

272 At the 1-year follow-up, the ISPF group demonstrated greater lumbar lordosis (LL:
273 $45.13^\circ \pm 4.97$ vs. $40.37^\circ \pm 7.37$; $P = 0.0002$) and lower pelvic tilt (PT: $12.49^\circ \pm$
274 7.62 vs. $15.80^\circ \pm 8.26$; $P = 0.0334$) compared with the PLIF group, indicating
275 superior sagittal balance restoration. The PLIF cohort achieved a smaller
276 segmental angle (SA: $10.99^\circ \pm 2.53$ vs. $12.52^\circ \pm 1.48$; $P=0.0004$), reflecting more
277 effective segmental angle correction. Additionally, disc height restoration was
278 greater in the ISPF group (13.76 ± 2.92 mm vs. 10.99 ± 2.34 mm; $P = 0.0001$).

279 These differences persisted through the final follow-up.

280 **Clinical outcomes**

281 Tables 4 and 5 and Figures 4, 5, and 6 present the clinical outcomes for the two
282 groups. The preoperative VAS score did not differ between the ISPF and PLIF
283 groups ($P = 0.9409$). The ISPF cohort, however, experienced greater pain relief

284 immediately postoperatively and at the 3-month follow-up. At the 1-year and final
 285 follow-up, the VAS scores were comparable between the groups (both $P > 0.05$).

Index	ISPF group (n=36)	PLIF group (n=36)	P value
VAS score, $\bar{x} \pm s$			
Preoperatively	7.05 ± 1.30	7.07 ± 1.18	0.9409
Postoperatively	$2.52 \pm 1.39^*$	$3.21 \pm 1.23^*$	0.0078
3 months postoperatively	$1.83 \pm 1.31^*$	$2.54 \pm 1.20^*$	0.0042
1 year follow-up	0.78 ± 1.37	1.07 ± 1.22	0.2435
At final follow-up	0.62 ± 1.33	0.92 ± 1.22	0.2284
JOA score, $\bar{x} \pm s$			
Preoperatively	19.77 ± 2.32	20.16 ± 2.47	0.3999
Postoperatively	23.33 ± 2.26	22.86 ± 2.42	0.3119
3 months postoperatively	25.17 ± 2.34	24.62 ± 2.66	0.2666
1 year follow-up	27.15 ± 2.37	27.15 ± 2.50	0.9799
At final follow-up	27.79 ± 2.32	27.70 ± 2.53	0.8347
ODI score, $\bar{x} \pm s$			
Preoperatively	55.63 ± 8.80	56.22 ± 6.75	0.6982
Postoperatively	$38.64 \pm 8.86^*$	$42.17 \pm 6.77^*$	0.0221
3 months postoperatively	$25.61 \pm 8.84^*$	$30.15 \pm 6.75^*$	0.0035
1 year follow-up	10.61 ± 8.79	12.29 ± 6.70	0.2648
At final follow-up	7.62 ± 8.81	7.21 ± 6.80	0.7833
Macnab Grading of Clinical Outcome			
Excellent	18	17	-
Good	13	13	-
Fair	5	6	-
Poor	0	0	-


Excellent-Good Rate(%)	86.11	83.33	$\chi^2 = 0.12, P = 0.9420$
□ □	PLIF (N=36)	Group ISPF Group (N=36)	□ P value
Operative time (min)	265.23 ± 6.85	168.31 ± 7.36	<0.001
Fluoroscopy times	18.61 ± 1.63	8.68 ± 1.09	<0.001
Intraoperative blood loss (mL)	122.45 ± 5.22	86.58 ± 4.68	0.002
Length of hospital stay (days)	14.21 ± 0.96	10.98 ± 0.75	< 0.001
Total length of incision (cm)	8.61 ± 0.79	5.12 ± 0.88	<0.001
□	□	□	□

286 **Table 4** Comparison of clinical scores between the ISPF and PLIF groups

287


288 **Table 5** Comparison of perioperative data between the two groups

289 JOA scores improved significantly from baseline at all postoperative time points in
 290 both cohorts (all $P < 0.05$), with no significant intergroup differences observed (all
 291 $P > 0.05$). According to the Macnab criteria, the excellent-to-good rates were
 292 86.11% in the ISPF group and 83.33% in the PLIF group ($\chi^2 = 0.12; P = 0.9420$)
 293 (Figures 4, 5, and 6).



294


295 **Figure 4.** Preoperative and postoperative imaging of a patient who underwent
 296 posterior lumbar interbody fusion (PLIF). (A, C) Images before the operation
 297 showing L4-L5 spondylolisthesis and lumbar spinal stenosis. (B, D) Images after
 298 PLIF demonstrating satisfactory pedicle screw fixation and interbody fusion with
 299 adequate reduction and decompression



300

301 **Figure 5.** Preoperative and postoperative images of ISPF. (A1, A2; B1-B4)
 302 Preoperative images demonstrating lumbar spinal stenosis and segmental
 303 instability at L4-L5. (C1-C3) Postoperative images showing satisfactory
 304 interspinous device implantation and decompression effects

305

306 **Figure 6.** Comparison of clinical outcomes between the ISPF and PLIF groups.

307 (A) Visual analog scale (VAS) scores, (B) Japanese Orthopaedic Association (JOA)

308 scores, and (C) Oswestry Disability Index (ODI) scores were recorded

309 preoperatively, postoperatively, at 3 months, 1 year, and at the last follow-up. *P

310 < 0.05 indicates a significant difference between groups at the corresponding time

311 point

312 Overall, the ISPF procedure conferred superior early outcomes in terms of pain

313 relief, functional recovery, and selected radiographic parameters, whereas PLIF

314 achieved greater correction of vertebral slippage. Importantly, both techniques

315 achieved comparable long-term clinical outcomes and patient-reported

316 satisfaction, suggesting that either approach represents a viable surgical option

317 for managing single-level DLS with concurrent LSS.

318 **Complications**

319 Over a follow-up period exceeding 24 months, at least one complication occurred
 320 in 16/36 (44.4%) patients in the PLIF group and 5/36 (13.9%) in the ISPF group (P
 321 = 0.0086; Table 6). Early complications (<90 days) were significantly lower in the
 322 ISPF group than in the PLIF group (2/36 [5.6%] vs 12/36 [33.3%], P = 0.0059).
 323 Early events included postoperative low back pain and lower-limb pain requiring
 324 intervention, surgical-site infection, dural tear, disc-space infection, and new or
 325 worsened neurologic deficit. Notably, no surgical-site infection or dural tear
 326 occurred in the ISPF group. Late complications (≥ 90 days) were comparable
 327 between groups (ISPF 3/36 [8.3%] vs PLIF 4/36 [11.1%], P = 1.0000). The
 328 reoperation rates were identical (2/36 [2.8%] vs 2/36 [2.8%], P = 1.0000).

Complication	PLIF (n=36)	ISPF (n=36)	P value
Overall complications	16 (44.4%)	5 (13.9%)	0.0086
Early (<90 days)	12 (33.3%)	2 (5.6%)	0.0059
Low back pain	4 (11.1%)	1 (2.8%)	0.3570
Lower limbs pain	3 (8.3%)	1 (2.8%)	0.6142
Surgical site infection	2 (5.6%)	0 (0.0%)	0.4930
Dural tear	2 (5.6%)	0 (0.0%)	0.4930
Disc space infection	0 (0.0%)	0 (0.0%)	1.0000
Neurologic deficit	1 (2.8%)	0 (0.0%)	1.0000
Late (≥ 90 days)	4 (11.1%)	3 (8.3%)	1.0000
Implant failure	2 (5.6%)	1 (2.8%)	1.0000

Reoperation	2 (5.6%)	2 (5.6%)	1.0000
-------------	----------	----------	--------

329 **Table 6** Complications within ≥ 24 Months after Surgery

330 Discussion

331 This study compared the clinical efficacy of ISPF and PLIF in the treatment of
 332 single-level degenerative LSS with Meyerding Grade I spondylolisthesis. These
 333 findings indicate distinct yet complementary therapeutic profiles for each
 334 technique. During the early postoperative phase (≤ 3 months), the ISPF technique
 335 resulted in superior improvement in clinical symptoms. However, at long-term
 336 follow-up (≥ 24 months), both groups achieved comparable clinical success rates.
 337 Radiographically, both techniques were associated with improvements in sagittal
 338 balance parameters. ISPF tended to maintain lumbar lordosis and disc height
 339 more effectively, whereas PLIF achieved greater correction of the slip angle.

340 The early clinical benefits of the ISPF procedure stem from its minimally invasive
 341 approach and dynamic stabilization mechanism. By achieving indirect
 342 decompression through distraction of the spinous processes, ISPF obviates
 343 extensive laminectomy and direct disc manipulation, thereby reducing soft-tissue
 344 trauma and subsequent inflammatory response. This approach facilitates
 345 accelerated functional recovery in properly indicated patients, particularly those
 346 with predominant neurogenic claudication symptoms[26]. Notably, even minimally
 347 invasive biportal or endoscopic interbody fusion remains technique-dependent and
 348 entails a substantial learning curve, with higher complication rates during the
 349 early phase of adoption[27]. In contrast, PLIF confers rigid stabilization through
 350 interbody fusion but necessitates more extensive surgical exposure and soft-tissue

351 dissection. The safety of transforaminal interbody fusion variants is highly
352 technique-dependent because of the narrow working corridor (Kambin's triangle);
353 a recent CT-based 3D modeling study quantified the L4-L5 Kambin's triangle to
354 delineate a safer operating region and potentially reduce nerve injury during
355 TPLIF[28]. Despite the greater extent of intraoperative trauma, PLIF achieves
356 superior restoration of disc height and segmental angle correction, resulting in a
357 radiographic advantage in postoperative assessments[14]. The biomechanical
358 advantage of PLIF becomes increasingly evident as fusion matures, ultimately
359 leading to comparable long-term clinical outcomes between the two techniques
360 despite their differing stabilization mechanisms.

361 These findings align with the contemporary literature while contributing
362 methodological and interpretative innovations. Jung et al. reported that ISPF
363 patients achieved more rapid improvements in VAS and ODI scores, accompanied
364 by significantly lower intraoperative blood loss and shorter operative times[26].
365 By applying propensity score matching (PSM) to control for confounders such as
366 age, BMI, symptom duration, and smoking history, our study strengthens these
367 observations with improved statistical validity. Long-term follow-up studies have
368 also reported comparable clinical efficacy between ISPF and PLIF, including the
369 2-year evaluation by Chen et al. evaluation in elderly patients[29], the 4-year
370 longitudinal analysis by Spallone[15], and the large retrospective cohort study by
371 Sabatino et al.[30]. With a minimum of 24 months of follow-up, our data not only
372 corroborate these conclusions but also refine patient selection criteria, suggesting

373 that ISPF may be preferable for cases requiring early functional recovery, whereas
374 PLIF may be more appropriate for patients with significant spinal instability or
375 advanced disc degeneration.

376 Our findings partially align with those of previous studies. While PLIF achieved
377 greater slip correction, ISPF showed greater disc height preservation and
378 comparable sagittal alignment. Fusion rate assessment was not included in our
379 study; thus, no definitive conclusion can be drawn regarding fusion superiority.

380 Notably, our study is among the first to systematically correlate radiographic
381 parameters with long-term clinical outcomes. We found that PLIF's radiographic
382 advantages did not translate into additional clinical benefits, thereby providing
383 objective, evidence-based insight to guide clinical surgical decision-making in
384 degenerative lumbar spine disease.

385 Current clinical evidence indicates safety advantages for the ISPF procedure.
386 Skoblar et al. reported lower incidences of infection, adjacent segment
387 degeneration, and device-related complications with ISPF compared with PLIF[31].

388 Chen et al. reported the efficacy of ISPF in moderate lateral recess stenosis,
389 though benefits were limited in severe central canal stenosis[23]. In this rigorously
390 matched cohort, the safety and perioperative advantages of ISPF were further
391 confirmed, highlighting its suitability for elderly patients, those with multiple
392 comorbidities or limited tolerance for surgery, and individuals desiring
393 accelerated postoperative recovery.

394 The principal strength of this study lies in its robust propensity score-matching

395 design, which achieved balanced baseline characteristics and effectively mitigated
396 potential confounders. The study's extended follow-up (≥ 24 months) and the novel
397 correlation of radiographic parameters with long-term clinical outcomes provides
398 valuable evidence to inform surgical decision-making. However, several
399 limitations warrant consideration. First, as a single-center, retrospective analysis
400 with a relatively modest sample size, the generalizability of our findings may be
401 constrained. Second, this investigation did not assess the incidence of adjacent
402 segment degeneration nor did it explore the underlying biomechanical
403 mechanisms in depth. Future research should prioritize multicenter randomized
404 controlled trials with standardized radiographic protocols, longer-term
405 surveillance for ASD (≥ 5 years), and the incorporation of performance-based
406 functional assessments to further elucidate the comparative effectiveness of these
407 surgical approaches.

408 **Conclusions**

409 This propensity score-matched comparative study with a minimum follow-up of 24
410 months provides clinically relevant insights for surgical strategy selection in
411 single-level degenerative lumbar spinal stenosis patients with Meyerding Grade I
412 spondylolisthesis. The findings indicate that: (1) ISPF offers superior early
413 recovery advantages with lower perioperative morbidity, making it particularly
414 suitable for elderly patients and those with multiple comorbidities; (2) PLIF may
415 be more appropriate for patients requiring greater vertebral slip correction or
416 rigid fixation, whereas ISPF offers an effective and less invasive alternative for

417 patients prioritizing faster recovery. These evidence-based conclusions enable
418 spine surgeons to optimize individualized treatment selection based on patient-
419 specific factors including age, comorbidity profile, spinal stability requirements,
420 and postoperative rehabilitation goals.

421 **Acknowledgements**

422 We thank our colleagues at the Sixth Medical Center of the PLA General Hospital
423 for their support.

424 **Funding**

425 This work was supported by the project "Research on Integrative Chinese and
426 Western Medicine Strategies Emphasizing Musculoskeletal Treatment for the
427 Rehabilitation and Health Preservation of Spine-Origin Low Back and Leg Pain."
428 (Grant No. 24BJZ07).

429 The authors express their gratitude for this financial support.

430 **Author information**

431 Authors and affiliations:

432 Orthopedics of TCM Senior Department, The Sixth Medical Center of People's
433 Liberation Army General Hospital, Beijing, China

434 Jingbo Ma, Yu Ding, Tusheng Li, Nan Shen, Rigbat Rozi

435 Navy Clinical College, Fifth School of Clinical Medicine, Anhui Medical University,

436 Hefei, China

437 Jingbo Ma, Yu Ding

438 Department of Orthopedics, Beijing Chaoyang Hospital, Capital Medical

439 University, Beijing, China

440 Tusheng Li

441 **Contributions**

442 J.M.: Writing – original draft, Writing – review & editing, Visualization, Validation,

443 Methodology, Formal analysis, Data curation. T.L.: Data curation, Formal analysis,

444 Writing – review & editing. N.S.: Investigation, Data curation, Writing – review &

445 editing. R.R.: Validation, Writing – review & editing. Y.D.: Corresponding author,

446 Resources, Software, Funding acquisition, Writing – review & editing, Supervision.

447 All authors have read, revised, and approved the final manuscript.

448 Corresponding author:

449 Correspondence to Yu Ding.

450 **Ethics declarations**

451 Ethics approval and consent to participate:

452 All procedures performed were in accordance with the ethical standards of the

453 institutional review board and with the 1964 Helsinki Declaration and its later

454 amendments or comparable ethical standards. The study was approved by the

455 Ethics Review Committee of the Sixth Medical Center of the General Hospital of
456 the Chinese People's Liberation Army (No. HZKY-PJ-2025-29).

457 **Consent for publication:**

458 Not applicable.

459 **Competing interests**

460 The authors declare that they have no known competing financial interests or
461 personal relationships that could have appeared to influence the work reported in
462 this paper.

463 **Data availability**

464 The datasets used during the current study are available from the corresponding
465 author on reasonable request.

466 **References**

- 467 1. Saremi A, Goyal KK, Benzel EC, Orr RD. Evolution of lumbar degenerative
468 spondylolisthesis with key radiographic features. *Spine J.* 2024;24:989-1000.
469 <https://doi.org/10.1016/j.spinee.2024.01.001>
- 470 2. Wang YXJ, Káplár Z, Deng M, Leung JCS. Lumbar degenerative
471 spondylolisthesis epidemiology: A systematic review with a focus on gender-
472 specific and age-specific prevalence. *J Orthop Translat.* 2017;11:39-52.
473 <https://doi.org/10.1016/j.jot.2016.11.001>
- 474 3. Bahir AW, Daxing W, Jiayu X, Bailian L, Shao G. Comparative efficacy and fusion
475 outcomes of unilateral bi-portal endoscopic transforaminal lumbar interbody
476 fusion versus minimally invasive transforaminal lumbar interbody fusion in
477 treating single-segment degenerative lumbar spondylolisthesis with lumbar spinal
478 stenosis: A two-year retrospective study. *J Orthop Surg Res.* 2024;19:835.
479 <https://doi.org/10.1186/s13018-024-05315-5>

480 4. Ammendolia C, Hofkirchner C, Plener J, et al. Non-operative treatment for
481 lumbar spinal stenosis with neurogenic claudication: An updated systematic
482 review. *BMJ Open*. 2022;12:e057724. <https://doi.org/10.1136/bmjopen-2021-057724>

484 5. Arunakul R, Anumas S, Patharanitima P, Susrivaraput C, Pholsawatchai W.
485 Unilateral biportal endoscopic versus microscopic transforaminal lumbar
486 interbody fusion for lumbar degenerative disease: A retrospective study. *J Orthop
487 Surg Res*. 2024;19:326. <https://doi.org/10.1186/s13018-024-04813-w>

488 6. Ball JR, Gallo MC, Kebaish K, et al. National trends in lumbar degenerative
489 spondylolisthesis with stenosis treated with fusion versus decompression.
490 *Neurospine*. 2024;21:1068-77. <https://doi.org/10.14245/ns.2448624.312>

491 7. Wang T, Ding W. Risk factors for adjacent segment degeneration after posterior
492 lumbar fusion surgery in treatment for degenerative lumbar disorders: A meta-
493 analysis. *J Orthop Surg Res*. 2020;15:582. <https://doi.org/10.1186/s13018-020-02032-7>

495 8. Chen M, Tang H, Shan J, et al. A new interspinous process distraction device
496 BacFuse in the treatment of lumbar spinal stenosis with 5 years follow-up study.
497 *Medicine (Baltimore)*. 2020;99:e20925.
498 <https://doi.org/10.1097/MD.00000000000020925>

499 9. Epstein NE, Agulnick MA. Perspective: Efficacy and outcomes for different
500 lumbar interspinous devices (ISD) vs. open surgery to treat lumbar spinal stenosis
501 (LSS). *Surg Neurol Int*. 2024;15:17. https://doi.org/10.25259/SNI_1007_2023

502 10. Zheng X, Chen Z, Yu H, Zhuang J, Yu H, Chang Y. A minimum 8-year follow-up
503 comparative study of decompression and coflex stabilization with decompression
504 and fusion. *Exp Ther Med*. 2021;21:595. <https://doi.org/10.3892/etm.2021.10027>

505 11. Li T, Yan J, Ren Q, Hu J, Wang F, Liu X. Efficacy and safety of lumbar dynamic
506 stabilization device coflex for lumbar spinal stenosis: A systematic review and
507 meta-analysis. *World Neurosurg*. 2023;170:7-20.
508 <https://doi.org/10.1016/j.wneu.2022.11.141>

509 12. Chen JW, Maldonado DR, Kowalski BL, et al. Best practice guidelines for
510 propensity score methods in medical research: Consideration on theory,
511 implementation, and reporting. A review. *Arthroscopy*. 2022;38:632-42.
512 <https://doi.org/10.1016/j.arthro.2021.06.037>

513 13. Austin PC. Optimal caliper widths for propensity-score matching when
514 estimating differences in means and differences in proportions in observational
515 studies. *Pharm Stat*. 2011;10:150-61. <https://doi.org/10.1002/pst.433>

516 14. Fenton-White HA. Trailblazing: The historical development of the posterior
517 lumbar interbody fusion (PLIF). Spine J. 2021;21:1528-41.
518 <https://doi.org/10.1016/j.spinee.2021.03.016>

519 15. Spallone A. Long term results of the use of a fusion-promoting, new generation
520 interspinous processes device (IPD), bacfuse®: A monocentric prospective study.
521 Eur Rev Med Pharmacol Sci. 2022;26:7561-5.
522 https://doi.org/10.26355/eurrev_202210_30030

523 16. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual
524 analogue scales as ratio scale measures for chronic and experimental pain. Pain.
525 1983;17:45-56. [https://doi.org/10.1016/0304-3959\(83\)90126-4](https://doi.org/10.1016/0304-3959(83)90126-4)

526 17. Vianin M. Psychometric properties and clinical usefulness of the oswestry
527 disability index. J Chiropr Med. 2008;7:161-3.
528 <https://doi.org/10.1016/j.jcm.2008.07.001>

529 18. Fukui M, Chiba K, Kawakami M, et al. Japanese orthopaedic association back
530 pain evaluation questionnaire. Part 2. Verification of its reliability: The
531 subcommittee on low back pain and cervical myelopathy evaluation of the clinical
532 outcome committee of the Japanese orthopaedic association. J Orthop Sci.
533 2007;12:526-32. <https://doi.org/10.1007/s00776-007-1168-4>

534 19. Fujimori T, Okuda S, Iwasaki M, et al. Validity of the Japanese orthopaedic
535 association scoring system based on patient-reported improvement after posterior
536 lumbar interbody fusion. Spine J. 2016;16:728-36.
537 <https://doi.org/10.1016/j.spinee.2016.01.181>

538 20. Legaye J, Duval-Beaupère G, Hecquet J, Marty C. Pelvic incidence: A
539 fundamental pelvic parameter for three-dimensional regulation of spinal sagittal
540 curves. Eur Spine J. 1998;7:99-103. <https://doi.org/10.1007/s005860050038>

541 21. Barrey C, Jund J, Noseda O, Roussouly P. Sagittal balance of the pelvis-spine
542 complex and lumbar degenerative diseases. A comparative study about 85 cases.
543 Eur Spine J. 2007;16:1459-67. <https://doi.org/10.1007/s00586-006-0294-6>

544 22. Diebo BG, Balmaceno-Criss M, Lafage R, et al. Sagittal alignment in the
545 degenerative lumbar spine: Surgical planning. JBJS. 2024;106:445.
546 <https://doi.org/10.2106/JBJS.23.00672>

547 23. Chen X, Li X, Wang Y, Lu S. Relation of lumbar intervertebral disc height and
548 severity of disc degeneration based on pfirrmann scores. Heliyon. 2023;9:e20764.
549 <https://doi.org/10.1016/j.heliyon.2023.e20764>

550 24. Kunkel ME, Herkommer A, Reinehr M, Böckers TM, Wilke H-J. Morphometric
551 analysis of the relationships between intervertebral disc and vertebral body

552 heights: An anatomical and radiographic study of the human thoracic spine. *J Anat.*
553 2011;219:375-87. <https://doi.org/10.1111/j.1469-7580.2011.01397.x>

554 25. Lee NJ, Mathew J, Kim JS, et al. Flexion-extension standing radiographs
555 underestimate instability in patients with single-level lumbar spondylolisthesis:
556 Comparing flexion-supine imaging may be more appropriate. *Journal of Spine*
557 *Surgery*. AME Publishing Company; 2021;7:48-54. <https://doi.org/10.21037/jss-20-631>

559 26. Jung S-C, Jung J-H, Hong J-H, Han M-S, Lee S-S, Lee J-K. The efficacy and
560 safety of decompression with interspinous fixation for lumbar spondylolisthesis
561 when compared with posterior lumbar interbody fusion: A pilot study. *Medicine*
562 (Baltimore). 2024;103:e38501. <https://doi.org/10.1097/MD.00000000000038501>

563 27. Guo W, Ye J, Li T, Yu Y, Fan X. Evaluation of the learning curve and
564 complications in unilateral biportal endoscopic transforaminal lumbar interbody
565 fusion: Cumulative sum analysis and risk-adjusted cumulative sum analysis. *J*
566 *Orthop Surg Res.* 2024;19:194. <https://doi.org/10.1186/s13018-024-04674-3>


567 28. Wang W, Cui Y, Sun X, et al. Transforaminal posterior lumbar interbody fusion
568 microscopic safe operating area: a three-dimensional model study based on
569 computed tomography imaging. *J Orthop Surg Res.* 2024;19:342.
570 <https://doi.org/10.1186/s13018-024-04830-9>


571 29. Chen M, Jia P, Feng F, Tang H. A novel minimally invasive technique of inter-
572 spinal distraction fusion surgery for single-level lumbar spinal stenosis in
573 octogenarians: A retrospective cohort study. *J Orthop Surg Res.* 2022;17:100.
574 <https://doi.org/10.1186/s13018-022-03004-9>


575 30. Orlando V, Galieri G, Mazzucchi E, et al. Comparative analysis of pedicle screw
576 fixation and interspinous devices in lumbar spinal fusion: Clinical and surgical
577 outcomes in degenerative spine conditions. *Journal of Personalized Medicine.*
578 2025;15:95. <https://doi.org/10.3390/jpm15030095>


579 31. Skoblar M, Hedman T, Rogers AJ, Jasper GP, Beall DP. Instrumented posterior
580 arthrodesis of the lumbar spine: Prospective study evaluating fusion outcomes in
581 patients receiving an interspinous fixation device for the treatment of
582 degenerative spine diseases. *J Pain Res.* 2023;16:2909-18.
583 <https://doi.org/10.2147/JPR.S417319>


584














Table 1 Baseline characteristics before PSM

Variable	PLIF Group	ISPF Group	P-value	SMD
Age	61.13 ± 6.71	58.43 ± 6.49	0.0366*	0.4092*
BMI	25.09 ± 2.62	24.04 ± 2.36	0.0313*	0.4216*
Disease Duration	28.16 ± 5.54	30.30 ± 5.25	0.0425*	0.3969*
Follow-Up Time	45.14 ± 2.05	45.90 ± 2.31	0.0762	0.3470*
Sex	22 (42.31%)	26 (47.27%)	0.7477	0.0998
Hypertension	27 (51.92%)	28 (50.91%)	1.0000	0.0203
Diabetes	17 (32.69%)	24 (43.64%)	0.3346	0.2253*
Smoking	42 (80.77%)	38 (69.09%)	0.2431	0.2694*
L3-L4	9 (17.31%)	10 (18.18%)	1.0000	0.0229
L4-L5	37 (71.15%)	37 (67.27%)	0.8219	0.0841
L5-S1	6 (11.54%)	8 (14.55%)	0.8617	0.0893

□ □ □ □ □

Table 2 Baseline characteristics after PSM

Variable	PLIF Group	ISPF Group	P-value	SMD
Age	59.23 ± 6.91	59.60 ± 6.06	0.8261	0.0579
BMI	24.43 ± 2.16	24.18 ± 2.27	0.6695	0.1127
Disease Duration	30.74 ± 4.69	30.29 ± 5.68	0.7461	0.0854
Follow-Up Time	45.44 ± 2.06	45.57 ± 2.08	0.8122	0.0627
Sex	15 (41.67%)	15 (41.67%)	1.0000	0.0000
Hypertension	17 (47.22%)	19 (52.78%)	0.6374	0.1113
Diabetes	16 (44.44%)	12 (33.33%)	0.3336	0.2294
Smoking	26 (72.22%)	25 (69.44%)	0.7954	0.0611
L3-L4	8 (22.22%)	6 (16.67%)	0.5515	0.1407
L4-L5	25 (69.44%)	25 (69.44%)	1.0000	0.0000
L5-S1	3 (10.34%)	5 (13.89%)	0.4533	0.1775
□	□	□	□	□

Table 3 Comparison of radiographic parameters of DLS-LSS patients between 2 groups

Parameter	PLIF group (N=36)	ISPF group (N=36)	P value
LL(°) , $\bar{x} \pm s$			
Preoperatively	39.06 \pm 11.48	40.90 \pm 11.21	0.4043
3 months	43.93 \pm 9.05	45.98 \pm 7.07	0.1922
postoperatively			
1 year follow-up	40.37 \pm 7.37*	45.13 \pm 4.97*	0.0002
At final follow-up	40.28 \pm 8.30*	43.37 \pm 6.94*	0.0388
PI(°) , $\bar{x} \pm s$			
Preoperatively	62.32 \pm 9.83*	57.39 \pm 10.91*	0.0159
3 months	57.18 \pm 9.97	56.47 \pm 8.73	0.6946
postoperatively			
1 year follow-up	58.92 \pm 10.22	59.43 \pm 8.60	0.7829
At final follow-up	59.10 \pm 9.51	57.73 \pm 8.61	0.4334
PT(°) , $\bar{x} \pm s$			
Preoperatively	18.05 \pm 9.36	19.46 \pm 7.77	0.3968
3 months	14.94 \pm 6.01	14.59 \pm 6.38	0.7738
postoperatively			
1 year follow-up	15.80 \pm 8.26	12.49 \pm 7.62	0.0334
At final follow-up	15.77 \pm 7.84*	11.69 \pm 6.75*	0.0047
SA(°) , $\bar{x} \pm s$			
Preoperatively	8.07 \pm 3.15	8.46 \pm 3.42	0.5435
3 months	11.51 \pm 2.18	11.61 \pm 2.96	0.8350
postoperatively			
1 year follow-up	10.99 \pm 2.53*	12.52 \pm 1.48*	0.0004
At final follow-up	10.34 \pm 2.59*	12.05 \pm 1.91*	0.0003
DH(mm) , $\bar{x} \pm s$			
Preoperatively	8.77 \pm 1.82	8.58 \pm 2.23	0.6259
3 months	11.64 \pm 3.66	12.69 \pm 3.30	0.1220
postoperatively			
1 year follow-up	10.99 \pm 2.34*	13.76 \pm 2.92*	0.0001
At final follow-up	10.77 \pm 2.87*	12.93 \pm 3.09*	0.0003

□

□

□

□

Table 4 Comparison of clinical scores between the ISPF and PLIF groups

Index	ISPF group (n=36)	PLIF group (n=36)	P value
VAS score, $\bar{x} \pm s$			
Preoperatively	7.05 \pm 1.30	7.07 \pm 1.18	0.9409
Postoperatively	2.52 \pm 1.39*	3.21 \pm 1.23*	0.0078
3 months	1.83 \pm 1.31*	2.54 \pm 1.20*	0.0042
postoperatively			
1 year follow-up	0.78 \pm 1.37	1.07 \pm 1.22	0.2435
At final follow-up	0.62 \pm 1.33	0.92 \pm 1.22	0.2284
JOA score, $\bar{x} \pm s$			
Preoperatively	19.77 \pm 2.32	20.16 \pm 2.47	0.3999
Postoperatively	23.33 \pm 2.26	22.86 \pm 2.42	0.3119
3 months	25.17 \pm 2.34	24.62 \pm 2.66	0.2666
postoperatively			
1 year follow-up	27.15 \pm 2.37	27.15 \pm 2.50	0.9799
At final follow-up	27.79 \pm 2.32	27.70 \pm 2.53	0.8347
ODI score, $\bar{x} \pm s$			
Preoperatively	55.63 \pm 8.80	56.22 \pm 6.75	0.6982
Postoperatively	38.64 \pm 8.86*	42.17 \pm 6.77*	0.0221
3 months	25.61 \pm 8.84*	30.15 \pm 6.75*	0.0035
postoperatively			
1 year follow-up	10.61 \pm 8.79	12.29 \pm 6.70	0.2648
At final follow-up	7.62 \pm 8.81	7.21 \pm 6.80	0.7833
Macnab Grading of Clinical Outcome			
Excellent	18	17	-
Good	13	13	-
Fair	5	6	-
Poor	0	0	-
Excellent-Good	86.11	83.33	$\chi^2 = 0.12, P = 0.9420$
Rate(%)			

Table 5 Comparison of perioperative data between two groups

□	PLIF Group (N=36)	ISPF Group (N=36)	P value
Operative time (min)	265.23 ± 6.85	168.31 ± 7.36	<0.001
Fluoroscopy times	18.61 ± 1.63	8.68 ± 1.09	<0.001
Intraoperative blood loss (mL)	122.45 ± 5.22	86.58 ± 4.68	0.002
Length of hospital stay (days)	14.21 ± 0.96	10.98 ± 0.75	< 0.001
Total length of incision (cm)	8.61 ± 0.79	5.12 ± 0.88	<0.001
□	□	□	□

Table 6 Complications within >24 Months after surgery

Complication	PLIF (n=36)	ISPF (n=36)	P value
Overall complications	16 (44.4%)	5 (13.9%)	0.0086
Early (<90 days)	12 (33.3%)	2 (5.6%)	0.0059
Low back pain	4 (11.1%)	1 (2.8%)	0.3570
Lower limbs pain	3 (8.3%)	1 (2.8%)	0.6142
Surgical site infection	2 (5.6%)	0 (0.0%)	0.4930
Dural tear	2 (5.6%)	0 (0.0%)	0.4930
Disc space infection	0 (0.0%)	0 (0.0%)	1.0000
Neurologic deficit	1 (2.8%)	0 (0.0%)	1.0000
Late (≥ 90 days)	4 (11.1%)	3 (8.3%)	1.0000
Implant failure	2 (5.6%)	1 (2.8%)	1.0000
Reoperation	2 (5.6%)	2 (5.6%)	1.0000